Five years ago, a trio of recent Carnegie Mellon University graduates hatched an idea for a new pediatric heart valve, spending nights and weekends developing the device in a small storefront they leased in Etna next door to a tattoo shop.

Five years later, they’re in a much nicer office space in Lawrenceville, across from Children’s Hospital.

More importantly, they’ve just been handed the keys to hospital surgical suites throughout Europe.

Earlier this spring, the three PECAlabs founders — CEO Doug Bernstein, 26, COO Jamie Quinterno, 27, and Chief Scientific Officer Arush Kalra, 30 — learned they’ve received European CE mark certification, akin to FDA approval in the U.S., for an innovative conduit called exGraft for use in children’s heart surgery. The conduit allows surgeons to detect any twisting or kinking, said Ergin Kocyildirim, a pediatric cardiothoracic surgeon at Children’s.

Advertise with us

“As there are marked visible lines [on the exGraft], this is both helpful to estimate measurements at the operating table and to follow up by a simple x-ray, instead of a CT scan,” significantly reducing the amount of radiation to the patient, he said.

It’s not their centerpiece product Masa valve, named in honor of former Children’s surgeon Masahiro Yoshida. But it’s a start.

After meeting with pediatric cardiac surgeons in seven European countries last month, they are now talking to distributors there to market exGraft as they work toward hoped-for FDA approval and a piece of the $10 billion heart valve market.

As they prepare for the next big step, they’ve added two more full-time employees: Susan Speicher as director of quality and regulatory affairs, and Denver Falk, as director of pre-clinical development.

“There’s a point where you have to go from a startup to a real company,” said Mr. Quinterno, and clearly they believe PECAlabs — the name is inspired by their specialization in pediatric cardiovascular devices — has hit that threshold.

Advertise with us

The Masa valve and exGraft use a material derived from Gore-Tex known as ePTFE, or expanded polytetrafluoroethylene, which they have modified so “it is half as thick but three times as strong,” said Mr. Bernstein.

Currently, patients that need a new heart valve or a graft on a blood vessel face two primary alternatives: pig or human tissue valves for children, which will calcify and deteriorate over time, while adults may also get a mechanical valve, which will require a life-long regimen of blood thinning medications to prevent strokes.

Future PECAlabs products will split the difference, using a sturdy material that they are designing to expand and thus prevent the need for additional surgeries as the child grows, but that is also biocompatible so only a daily small-dose aspirin is needed to stop blood clots from forming.

When it became clear the regulatory process for the Masa heart valve would take longer than expected, the trio began work on three related products, with exGraft the first to go to market.

“It’s not like we were going to sit around waiting,” said Mr. Bernstein.

Advertise with us

PECAlabs was founded in 2012, a self-described spinoff of CMU and the University of Pittsburgh, and the co-founders’ drive to make medical devices that help pediatric heart surgeons has not lagged.

“We’re not passionate about anything except what we’re working on,” said Mr. Quinterno, who suggested that may explain why the three remain single. “You can’t commit a venture like this, and take the personal risk, if people are counting on you to put food on the table.”

There were some frustrating lessons along the way, particularly when it came to selling their idea to investors. “People who came through for us versus people who let us down was very difficult to predict,” said Mr. Bernstein.

To date, they’ve attracted nearly $4 million from angel investors and in grants, putting them on solid financial ground as they enter the European market. To commemorate their fifth anniversary and the CE mark milestone, they’ve planned a celebration on the North Side next week to thank their supporters.

“It’s definitely going to be nice to talk to people and not be asking for money,” Mr. Bernstein said.

Steve Twedt: stwedt@post-gazette.com or 412-263-1963.